MedTrace Logo

Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.

NCT00193882 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2017-07-12

No results posted yet for this study

Summary

To compare the treatment of gullet cancer with radiotherapy alone and assess the advantage and toxicity of adding chemotherapy. The hypothesis to be tested is as follows: That the addition of chemotherapy to a short course of radiation treatment improves the proportion of patients who achieve relief of dysphagia and improves quality of life compared to radiation alone in patients with advanced oesophageal cancer.

Conditions

  • Esophagus Cancer

Interventions

DRUG

Cisplatin

80mg/m2 IV day 1

RADIATION

Radiotherapy

35 Gy in 15 fractions

DRUG

5-Fluorouracil

800mg/m2/day IV days 1 - 4

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Canadian Cancer Trials Group

    collaborator NETWORK

  • Trans Tasman Radiation Oncology Group

    lead OTHER

Principal Investigators

  • Michael Penniment, FRANZCR · Royal Adelaide Hopsital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-07
Primary Completion
2012-03-21
Completion
2013-06-18

Countries

  • Australia
  • Canada
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00193882 on ClinicalTrials.gov